Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

References

• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Merli F, Bertini M, Luminari S, . Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:367–373.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Gherlinzoni F, Storti S, . Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002;13:1364–1369.
   PubMed Web of Science ®Google Scholar
• Luminari S, Montanini A, Caballero D, . Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010;21:1492–1499.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Gisselbrecht C, . Rituximab and reduced dose CHOP (R-mini-CHOP) for patients over 80 years with diffuse large B-cell lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B. Blood 2010;116(Suppl. 1): Abstract 853.
   Google Scholar
• Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000;35:147–154.
   PubMed Web of Science ®Google Scholar
• Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824–1831.
   PubMed Web of Science ®Google Scholar
• Miller MD, Towers A. A manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburg, PA: University of Pittsburg; 1991.
   Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65–74.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187–202.
   Google Scholar
• Armitage P, Berry G. Statistical methods in medical research. Oxford, UK: Blackwell; 1987.
   Google Scholar
• Wang R, Lagakos SW, Ware JH, . Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189–2194.
   PubMed Web of Science ®Google Scholar
• Shoenfeld D. Partial residuals for the proportional hazard regression model. Biometrika 1982;69:239–241.
   Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Marcos-Gragera R, Allemani C, Tereanu C, . Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica 2011;96:720–728.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H, . Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530–2539.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D, Van Glabbeke M, . CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27–34.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay JY, Divine M, . Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival—a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945–2953.
   PubMed Web of Science ®Google Scholar
• Hryniuk W, Frei E 3rd, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998;16:3137–3147.
   PubMed Web of Science ®Google Scholar
• Advani RH, Chen H, Habermann TM, . Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010;151:143–151.
   PubMed Web of Science ®Google Scholar
• Monfardini S, Ferrucci L, Fratino L, . Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395–401.
   PubMed Web of Science ®Google Scholar